Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study.

Liver international : official journal of the International Association for the Study of the Liver·2021
Same author

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.

Scientific reports·2021
Same author

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.

Viruses·2021
Same author

Letter to the editor: New kid in the playground: HBcrAg and risk of HCC.

Hepatology (Baltimore, Md.)·2021
Same author

Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.

Alimentary pharmacology & therapeutics·2021
Same author

Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).

Gastroenterology·2021

Related Experiment Video

Updated: Feb 18, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Unmet Needs in Clinical and Basic Hepatitis B Virus Research.

Tung-Hung Su1,2, Jia-Horng Kao1,2,3,4

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine.

The Journal of Infectious Diseases
|November 21, 2017
PubMed
Summary

Chronic hepatitis B (CHB) is manageable with current therapies, but unmet needs persist. Further research is crucial for optimizing treatment, improving HCC surveillance, and achieving a functional cure for CHB.

Keywords:
Nucleos(t)ide analoguesbiomarkercccDNAimmunotherapypegylated interferon

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Experiment Videos

Last Updated: Feb 18, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.7K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Area of Science:

  • Hepatology and Viral Hepatitis Research
  • Clinical and Translational Medicine
  • Molecular Virology

Background:

  • Chronic hepatitis B (CHB) is a treatable condition with nucleos(t)ide analogues (NUCs) and pegylated interferon, reducing disease progression and mortality.
  • Long-term NUC therapy offers effective viral suppression with few adverse effects, but significant clinical challenges remain.

Purpose of the Study:

  • To review unmet needs in the clinical management of CHB.
  • To identify key challenges in basic research for achieving a functional or complete cure of CHB.
  • To highlight areas requiring further investigation for improved patient outcomes.

Main Methods:

  • Literature review of current CHB therapies and research.
  • Analysis of existing clinical guidelines and emerging research trends.
  • Synthesis of information on challenges in basic HBV research.

Main Results:

  • Unmet needs include optimizing HCC surveillance in NUC-treated patients and defining criteria for finite-duration or combination therapies.
  • Management strategies for specific patient groups (e.g., HBeAg-positive) and biomarker integration require further study.
  • Basic research challenges involve developing better HBV models and treatments to eradicate cccDNA and achieve immunotherapy.

Conclusions:

  • Significant advancements have been made in CHB treatment, yet critical clinical and basic research gaps need addressing.
  • Achieving a functional cure (HBsAg seroclearance) and complete cure (cccDNA eradication) requires innovative approaches in virology and immunology.
  • Future research should focus on personalized treatment strategies, novel therapeutic targets, and robust preclinical models.